Anilinopyridines as inhibitors of fak

Inactive Publication Date: 2010-12-16
GLAXO SMITHKLINE LLC
View PDF2 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028]In a further embodiment, the present invention relates to a method of treating cancer comprising adm

Problems solved by technology

Furthermore, loss of FAK catalytic activity (reconstitution of FAK−/− cells with k

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anilinopyridines as inhibitors of fak
  • Anilinopyridines as inhibitors of fak
  • Anilinopyridines as inhibitors of fak

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1

[0106]N-Methyl-2-{[2-[2-oxo-2.3-dihydro-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyridinyl]amino}benzamide

[0107]2-{[2-Chloro-5-(trifluoromethyl)-4-pyridinyl]amino}-N-methylbenzamide (Intermediate 1, 50 mg, 0.152 mmol), 5-amino-1,3-dihydro-2H-indol-2-one (90 mg, 0.607 mmol), 1.0 M hydrochloric acid (0.3 mL) 1,4-dioxane (1.0 mL), and water (1.0 mL) were added to a vessel, which was sealed and heated at 150° C. for 2 days. The resulting crude material was purified by reverse-phase HPLC to give the title compound as a solid (20 mg, 26% yield). MS: M(C22H18F3N5O2)=441.41, (M+H)+=442; 1H NMR (400 MHz, DMSO-d6) δ ppm 2.76 (d, J=4.55 Hz, 3 H) 3.45 (s, 2 H) 6.68 (s, 1 H) 6.74 (d, J=8.34 Hz, 1 H) 7.11 (dd, J=15.03, 1.14 Hz, 1H) 7.26 (dd, J=8.46, 2.15 Hz, 1 H) 7.43-7.52 (m, 1 H) 7.54-7.60 (m, 1 H) 7.71 (dd, J=7.83, 1.26 Hz, 1 H) 8.18 (s, 1 H) 8.23 (s, 1 H) 8.67 (d, J=4.55 Hz, 1H) 9.07(s, 1 H) 10.15 (s, 1 H) 10.24 (s, 1 H).

Example

Example 2

[0108]N-Methyl-2-{[2-{[4-(4-morpholinyl)phenyl]amino}-5-(trifluoromethyl)-4-pyridinyl]amino}benzamide

[0109]A microwave tube was charged with 2-{[2-chloro-5-(trifluoromethyl)-4-pyridinyl]amino}-N-methylbenzamide (Intermediate 1, 60 mg, 0.182 mmol), 4-(4-morpholinyl)aniline (39.0 mg, 0.219 mmol) and 0.4 mL of 1.0 M hydrochloric acid in 2.5 mL of 1,4-dioxane, then irradiated in a microwave oven at 160° C. for 1 hour. The resulting crude material was purified using reverse-phase HPLC to give the title compound (23 mg, 23% yield). MS: M(C23H24F3N5O2)=471.48, (M+H)+=472; 1H NMR (400 MHz, DMSO-d6) δ ppm 2.76 (d, J=4.55 Hz, 3 H) 3.01-3.03 (m, 4 H) 3.72-3.74 (m, 4 H) 6.67 (s, 1 H) 6.88 (d, J=8.84 Hz, 2H) 7.10 (dd, J=15.03, 1.14 Hz, 1H) 7.41 (m, J=9.09 Hz, 2 H) 7.47-7.61 (m, 2 H) 7.70 (dd, J=7.83, 1.52 Hz, 1 H) 8.22 (s, 1 H) 8.67 (d, J=4.55 Hz, 1 H) 9.01 (s, 1 H) 10.15 (s, 1 H).

Example

Example 3

[0110]N-Methyl-2-{[2-{[-2-(methyloxy)-4-(4-morpholinyl)phenyl]amino}-5-(trifluoromethyl)-4-pyridinyl]amino}benzamide

[0111]2-{[2-Chloro-5-(trifluoromethyl)-4-pyridinyl]amino}-N-methylbenzamide (Intermediate 1, 50 mg, 0.152 mmol) and [2-(methyloxy)-4-(4-morpholinyl)phenyl]amine (148 mg, 0.607 mmol) were combined with 1M hydrochloric acid (0.303 mL, 0.303 mmol), 1,4-dioxane (0.2 mL) and water (2.5 mL) in a microwave tube, then irradiated in a microwave oven at 170° C. for 25 min. The resulting crude material was filtered and the filtrate was purified by reverse-phase HPLC to give the title compound (35.5 mg, 0.071 mmol, 46.7% yield). MS: M(C25H26F3N5O3)=471.48, (M+H)+=472; 1H NMR (400 MHz, METHANOL-d4) δ ppm 2.88 (s, 3 H), 3.05-3.14 (m, 4 H), 3.78-3.91 (m, 7 H), 6.45 (s, 1 H), 6.52 (dd, J=8.59, 2.53 Hz, 1 H), 6.64 (d, J=2.53 Hz, 1 H), 7.03-7.13 (m, 1 H), 7.30 (d, J=8.59 Hz, 1 H), 7.40-7.50 (m, 2 H), 7.61 (dd, J=7.83, 1.26 Hz, 1 H), 8.10 (s, 1 H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Frequencyaaaaaaaaaa
Frequencyaaaaaaaaaa
Frequencyaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein R1-R4, Q, Z, r, and p are as defined herein. Compounds of the present invention are useful in the treatment of diseases associated with FAK overexpression, including proliferative diseases.

Description

[0001]This invention relates to a class of anilinopyridines that inhibit Focal Adhesion Kinase (FAK), as well as compositions thereof. Compounds of the present invention are useful in the treatment of proliferative diseases.[0002]Tyrosine kinases play an important role in the regulation of many cell processes including cell proliferation, cell survival, and cell migration. It is known that certain tyrosine kinases become activated by mutation or are abnormally expressed in many human cancers. For example, the epidermal growth factor receptor (EGFR) is found mutated and / or overexpressed in breast, lung, brain, squamous cell, gastric, and other human cancers. Selective inhibitors of the tyrosine kinase activity of EGFR have been shown to be of clinical value in treatment of cancers with mutated and / or overexpressed EGFR. Thus, selective inhibitors of particular tyrosine kinases are useful in the treatment of proliferative diseases such as cancer.[0003]FAK (encoded by the gene PTK2) is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/5377C07D401/12C07D413/12A61K31/4439A61P35/00
CPCC07D401/12C07D213/74A61P35/00A61P43/00
Inventor ADAMS, JERRY LEROYFAITG, THOMAS H.JOHNSON, NEIL W.PENG, XIN
Owner GLAXO SMITHKLINE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap